131I-metaiodobenzylguanidine--a new agent for scintigraphic imaging and treatment of pheochromocytoma.
In 91 patients with a suspicion of pheochromocytoma 96 scintigraphies with 131I-metaiodobenzylguanidine were performed. The distribution of this radiopharmaceutical agent was studied. In about 71% we found uptake in the liver, in about 20% in the spleen and in about 6% in the gastrointestinal tract. In 13% of our patients a normal tracer uptake in the adrenal medulla was observed. In 23 patients adrenal or extra-adrenal lesion(s) were localized correctly, whereas one false-positive and one false-negative scintigramme was obtained. The 131I-MIBG imaging of adrenal and extra-adrenal, benign and malignant pheochromocytomas and adrenomedullary hyperplasia is highly specific. In the treatment of pheochromocytomas more experience is needed to present final results, but especially in malignant pheochromocytomas 131I-MIBG therapy may be useful.
D019797:3-Iodobenzylguanidine; D000293:Adolescent; D000310:Adrenal Gland Neoplasms / Q000000981:diagnostic imaging* / Q000532:radiotherapy; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D007462:Iodobenzenes; D008297:Male; D008875:Middle Aged; D010673:Pheochromocytoma / Q000000981:diagnostic imaging* / Q000532:radiotherapy; D011877:Radionuclide Imaging
D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D019797:3-Iodobenzylguanidine